It is a draw interferon-beta 1 vs. glatiramer acetate 1. #ClinicSpeak There is no difference in the comparative effectiveness between the beta-interferons and glatiramer acetate. But what about the other attributes, e.g. pregnancy, NABs, monitoring, etc. ? https://t.co/b6VygWzrQq pic.twitter.com/90qwG5wAtI— Gavin Giovannoni (@GavinGiovannoni) October 6, 2018
Having MS and other neurological conditions puts you at risk of in-hospital complications from having total Joint replacements. Some of these are preventable and need to be discussed with your surgeon and anaesthetist and possibly your neuro. #ClinicSpeak https://t.co/VLmSrkk5tR pic.twitter.com/q2ZxEJ6Zhk— Gavin Giovannoni (@GavinGiovannoni) October 6, 2018
Did you know that MS can cause sudden death? It typically occurs with an acute brainstem lesion. #ClinicSpeak Here are two case reports of brainstem relapses causing an acute cardiomyopathy. Who said active MS was not life threatening? https://t.co/MQ00vIMwDV pic.twitter.com/QTgH1XtSPM— Gavin Giovannoni (@GavinGiovannoni) October 6, 2018
Sure you want to miss this? Prof @GavinGiovannoni will be presenting: "A patient-centric approach in #multiplesclerosis care." Wednesday 10th Oct 15:00 CET at the #Actelion booth (C07) #ECTRIMS2018 #MS @ECTRIMS @actelion_com pic.twitter.com/ngGinsz4S5— Janssen Global (@JanssenGlobal) October 4, 2018
ProfG are you walking-your-talk or just huffing-and-puffing? This is about NICE's negative decision to allow us to prescribe ocrelizumab to PPMSers on the NHS. #PoliticalSpeak... https://t.co/yNkNMexttl pic.twitter.com/SxOGTWRjHA— Gavin Giovannoni (@GavinGiovannoni) October 4, 2018
The fact that the liver profile of teriflunomide is no different to interferon β is very reassuring. Why then do we need to monitor LFTs every 2 weeks for 6 months and then 2-monthly after that for Teri-treated MSers? Very frustrating. #ClinicSpeak https://t.co/RFXpsW3AyL pic.twitter.com/OU2DpAV8Xh— Gavin Giovannoni (@GavinGiovannoni) October 3, 2018
The Mouse Doctor thinks the Canadian MS Society wasted their money on producing the final nail for the CCSVI coffin. Do you agree? #ClinicSpeak https://t.co/xRn0VgPJPY pic.twitter.com/JhGd284ppX— Gavin Giovannoni (@GavinGiovannoni) October 3, 2018
Why manage comorbidities in people with #MultipleSclerosis? Download our summary of the evidence for healthcare professionals https://t.co/enzx6jQOfa #neurology #MS #health #lifestyle #heart #diabetes #mentalhealth pic.twitter.com/AAbUnQaY7Z— Gavin Giovannoni (@GavinGiovannoni) October 3, 2018
The table of MS mimics just gets longer. I think there are enough atypical features in this case to make MS unlikely. #ClinicSpeak Autoimmune encephalitis with elevated N-type calcium channel antibodies as a multiple sclerosis mimic. https://t.co/Kjq7nYxxd3 pic.twitter.com/fkB4ruANW3— Gavin Giovannoni (@GavinGiovannoni) October 2, 2018
Does one swallow make a summer? Looks as if DMF is not suitable for treating NMOSD. #CllinicSpeak Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate. https://t.co/bwuYLdSu5X pic.twitter.com/x3z6HEtSdm— Gavin Giovannoni (@GavinGiovannoni) October 2, 2018
Childhood MS is rare, very rare. This is why it is so hard to do DMT trials in this population. There are simply not enough children MSers. #ClinicSpeak Incidence and prevalence of MS in children: A population-based study in Canada. https://t.co/EEs6pUlrGC pic.twitter.com/NF8s1okuA8— Gavin Giovannoni (@GavinGiovannoni) October 1, 2018
Very exciting that other research groups are getting interested in social networks and how to measure them. #ClinicSpeak A scalable online tool for quantitative social network assessment reveals potentially modifiable social environmental risks. https://t.co/TmmzEojZpm pic.twitter.com/k6D7qZUocA— Gavin Giovannoni (@GavinGiovannoni) October 1, 2018
The fact that MS is less common than NMO in South-East Asia mean the McDonald criteria are likely to be less sensitive and specific outside high MS prevalence areas. Do we need a new set of diagnostic criteria for low MS prevalence areas? #NeuroSpeak https://t.co/EXjakAJlaf pic.twitter.com/YjsAHPMoTI— Gavin Giovannoni (@GavinGiovannoni) October 1, 2018
How can doctors get better at recognising and diagnosing #MS earlier? Aoife from shiftms interviews Prof Helmut Butzkueven https://t.co/YN66Z5Afrz #MultipleSclerosis #neurology— Gavin Giovannoni (@GavinGiovannoni) October 1, 2018
CoI: multiple